Correlation of ex vivo cytokine secretion profiles with scoring indices in ulcerative colitis.
IBD
MES
UCEIS
cytokines
endoscopic score
ulcerative colitis
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
12
07
2023
received:
02
01
2023
accepted:
17
07
2023
medline:
22
11
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
In ulcerative colitis, the complexity of mucosal cytokine secretion profiles and how they correlate with endoscopic and clinical scores is still unclear. In this study, we collected fresh biopsies from UC patients to investigate which cytokines are produced in ex vivo culture conditions, a platform increasingly used for testing of novel drugs. Then, we correlated cytokine production with several scoring indices commonly used to assess the severity of the disease. Increased levels of IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, TNFα and IFNɣ were produced by biopsies of UC patients compared to non-IBD controls. Our results show a better correlation of cytokine levels with Mayo Endoscopic Subscore (MES) and Mayo score, than the more complex Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Out of 10 measured cytokines, eight correlated with MES, six with Mayo score and only three with UCEIS, due to the partial increase in cytokine secretion observed in donors with UCEIS = 7-8. When we analysed individual subscores within the UCEIS, Vascular Network subscore showed a correlation similar to MES (7/10 cytokines), while Bleeding as well as Erosions and Ulcers subscores correlated with only 3/10 cytokines, similarly to the total UCEIS. Our findings suggest that choosing biopsies from donors with MES = 2-3 and UCEIS = 2-6 from areas with no bleeding and no superficial and/or deep ulcers could enable a deeper insight into the cytokine profile of the inflamed tissue and represent a better tool for studying potential therapeutic targets and evaluation of novel therapies.
Sections du résumé
BACKGROUND
BACKGROUND
In ulcerative colitis, the complexity of mucosal cytokine secretion profiles and how they correlate with endoscopic and clinical scores is still unclear.
METHODS
METHODS
In this study, we collected fresh biopsies from UC patients to investigate which cytokines are produced in ex vivo culture conditions, a platform increasingly used for testing of novel drugs. Then, we correlated cytokine production with several scoring indices commonly used to assess the severity of the disease.
RESULTS
RESULTS
Increased levels of IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, TNFα and IFNɣ were produced by biopsies of UC patients compared to non-IBD controls. Our results show a better correlation of cytokine levels with Mayo Endoscopic Subscore (MES) and Mayo score, than the more complex Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Out of 10 measured cytokines, eight correlated with MES, six with Mayo score and only three with UCEIS, due to the partial increase in cytokine secretion observed in donors with UCEIS = 7-8. When we analysed individual subscores within the UCEIS, Vascular Network subscore showed a correlation similar to MES (7/10 cytokines), while Bleeding as well as Erosions and Ulcers subscores correlated with only 3/10 cytokines, similarly to the total UCEIS.
CONCLUSIONS
CONCLUSIONS
Our findings suggest that choosing biopsies from donors with MES = 2-3 and UCEIS = 2-6 from areas with no bleeding and no superficial and/or deep ulcers could enable a deeper insight into the cytokine profile of the inflamed tissue and represent a better tool for studying potential therapeutic targets and evaluation of novel therapies.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14070Informations de copyright
© 2023 Stichting European Society for Clinical Investigation Journal Foundation.
Références
Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769-2778. doi:10.1016/S0140-6736(17)32448-0
Roda G, Marocchi M, Sartini A, Roda E. Cytokine networks in ulcerative colitis. Ulcers. 2011;2011:1-5. doi:10.1155/2011/391787
Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5):329-342. doi:10.1038/nri3661
Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769-784. doi:10.1093/ecco-jcc/jjx009
Nakase H, Sato N, Mizuno N, Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev. 2022;21(3):103017. doi:10.1016/j.autrev.2021.103017
Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020;18(10):2179-2191.e6. doi:10.1016/j.cgh.2020.01.008
Mullard A. Parsing clinical success rates. Nat Rev Drug Discov. 2016;15(7):447. doi:10.1038/nrd.2016.136
Dionne S, Laberge S, Deslandres C, Seidman EG. Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease. Clin Exp Immunol. 2003;133(1):108-114. doi:10.1046/J.1365-2249.2003.02191.X
Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009;58(12):1629-1636. doi:10.1136/GUT.2009.182170
Biancheri P, Di Sabatino A, Ammoscato F, et al. Absence of a role for interleukin-13 in inflammatory bowel disease. Eur J Immunol. 2014;44(2):370-385. doi:10.1002/EJI.201343524
León AJ, Gómez E, Garrote JA, et al. High levels of proinflammatory cytokines, but not markers of tissue injury, in unaffected intestinal areas from patients with IBD. Mediat Inflamm. 2009;2009:580450. doi:10.1155/2009/580450
Matsuda R, Koide T, Tokoro C, et al. Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid Naïve ulcerative colitis during active and quiescent disease. Inflamm Bowel Dis. 2009;15(3):328-334. doi:10.1002/ibd.20759
Tsukada Y, Nakamura T, Iimura M, Iizuka B, Hayashi N. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol. 2002;97(11):2820-2828. doi:10.1111/J.1572-0241.2002.07029.X
Raddatz D, Bockemühl M, Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol. 2005;17(5):547-557.
Butera A, Di Paola M, Vitali F, et al. IL-13 mRNA tissue content identifies two subsets of adult ulcerative colitis patients with different clinical and mucosa-associated microbiota profiles. J Crohns Colitis. 2020;14(3):369-380. doi:10.1093/ecco-jcc/jjz154
Lopetuso LR, Corbi M, Scaldaferri F, et al. Characterization of mucosal cytokine profile in ulcerative colitis patients under conventional and anti-TNF-a treatment. Eur J Gastroenterol Hepatol. 2020;32(12):1527-1532.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated Oral 5-Aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317(26):1625-1629. doi:10.1056/NEJM198712243172603
Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92(6):1894-1898. doi:10.1016/0016-5085(87)90621-4
Travis SPL, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the ulcerative colitis endoscopic index of severity (UCEIS). Gut. 2012;61(4):535-542. doi:10.1136/gutjnl-2011-300486
Travis SPL, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145(5):987-995. doi:10.1053/j.gastro.2013.07.024
Dawson B, Trapp RG. Basic & Clinical Biostatistics. 4th ed. McGraw Hill LLC; 2004 https://books.google.hr/books?id=p6hu-qU2zpsC
Corcoran RM, MacDonagh P, O'Connell F, et al. Association between ex vivo human ulcerative colitis explant protein secretion profiles and disease behaviour. Dig Dis Sci. 2022;67:5540-5550. doi:10.1007/s10620-022-07411-0
Mavroudis G, Magnusson MK, Isaksson S, et al. Mucosal and systemic immune profiles differ during early and late phases of the disease in patients with active ulcerative colitis. J Crohns Colitis. 2019;13(11):1450-1458. doi:10.1093/ecco-jcc/jjz072
Sanchez-Muñoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008;14(27):4280. doi:10.3748/WJG.14.4280
Nielsen OH, Kirman I, Rüdiger N, Hendel J, Vainer B. Upregulation of Interleukin-12 and -17 in active inflammatory bowel disease. Scand J Gastroenterol. 2003;38(2):180-185. doi:10.1080/00365520310000672
Wynn TA. IL-13 effector functions. Annu Rev Immunol. 2003;21(1):425-456. doi:10.1146/annurev.immunol.21.120601.141142
Kawashima R, Kawamura YI, Oshio T, et al. Interleukin-13 damages intestinal mucosa via TWEAK and Fn14 in mice-a pathway associated with ulcerative colitis. Gastroenterology. 2011;141(6):2119-2129.e8. doi:10.1053/j.gastro.2011.08.040
Yarkoni S, Sagiv Y, Kaminitz A, Askenasy N. Interleukin 2 targeted therapy in inflammatory bowel disease. Gut. 2009;58(12):1705-1706. doi:10.1136/gut.2008.175182
Mahida YR, Gallagher A, Kurlak L, Hawkey CJ. Plasma and tissue interleukin-2 receptor levels in inflammatory bowel disease. Clin Exp Immunol. 1990;82(1):75-80. doi:10.1111/j.1365-2249.1990.tb05406.x
Mullin GE, Lazenby AJ, Harris ML, Bayless TM, James SP. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology. 1992;102(5):1620-1627. doi:10.1016/0016-5085(92)91722-G
Schreiber S, Heinig T, Thiele H-G, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology. 1995;108(5):1434-1444. doi:10.1016/0016-5085(95)90692-4
Szkaradkiewicz A, Marciniak R, Chudzicka-Strugała I, et al. Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients. Arch Immunol Ther Exp. 2009;57(4):291-294. doi:10.1007/s00005-009-0031-z
Rogy MA, Beinhauer BG, Reinisch W, Huang L, Pokieser P. Transfer of Interleukin-4 and Interleukin-10 in patients with severe inflammatory bowel disease of the rectum. Hum Gene Ther. 2000;11(12):1731-1741. doi:10.1089/10430340050111386